ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / RVTY
AVTR (56) BIO (62) MTD (78) TXG (59) ⌘ Pro Terminal →

Revvity Inc. (RVTY) — RQD Stock Rating Cockpit

$157.00 -5.30% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $155.20

Revvity Inc. (RVTY) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY) →
ROARABLE C • HOLD / WATCH Cap $17.52B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RVTY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RVTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Revvity Inc. (NYSE: RVTY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $157.00 (-5.30% 1D, market cap $17.52B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RVTY ranks #115 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RVTY compare to AVTR and BIO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RVTY carries a Roarable C (65/100 RQD), trailing P/E of 76.7x, gross margin of —, and ROIC of 3.1%. By comparison, AVTR (Avantor Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC -2.1%, cap $10.88B) and BIO (Bio-Rad Laboratories Inc.) posts a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while MTD leads on capital efficiency (30.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RVTY?
▼

Per RVTY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000031791), Revvity Inc. generated $2.86B in revenue (+3.7% YoY), $241.2M in net income, and $509.4M in free cash flow against $12.17B in total assets and $2.63B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $155.21 (-1.14%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 17.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510065
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B-
Cash (12)Whales (16)SEC (16)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+3.2% Base Target
$191 Bull$162 Base$126 Bear
📬 FREE RVTY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RVTY)Realized 20D OHLCV Swing Band: ±7.2%
Deterministic 5-Pillar Attribution (65/100 Composite)
🔍 WHY RVTY SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (25% of score)

20D Institutional Volume Accumulation (±7.2% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)

Altman Z-Score 3.37 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
57
Grade C$152.12+3% Next Q
Q2 (-2Q)
60
Grade C$156.61+5.6% Next Q
Q3 (-1Q)
62
Grade C+$165.33-5% Next Q
Current
65
Grade C$157.00+1.3% Hist 90D α
Trajectory: C (57) → C (65)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RVTY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, RVTY faces multiple-compression risk if 76.7x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Priced at 77x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($146.80) or 200D SMA ($112.63) invalidates the momentum regime and cuts Target Base ($161.95) toward Bear Floor ($126.32).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RVTY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RVTY Beats Next Quarter EPS Consensus (Dec 27, 2026) & Holds Above 200D SMA”
YES 65%NO 35%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
51.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.37>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE86% OF RANGE
L: $81$157.00H: $169
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 25 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on RVTY

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

3.1% ROIC with 42.0% gross margin and 2.75% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 3.37 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
NEUTRAL (62)

25/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like RVTY
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Priced at 77x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (RVTY Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RVTY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +81.48%▲ ASCENDING CHANNEL
2026-11-03O $165.8H $165.8L $157.0C $157.0VOL 3.18M
RES: $180.7SUP: $141.0SMA50: $146.8SMA200: $112.6
$174.9$150.7$126.5$102.3$78.10RES $180.7SUP $141.0$157.02026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RVTY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RVTY Butterfly Map → + Track RVTY →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth

vs. +3.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RVTY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RVTY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RVTY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RVTY)

Health Care Rank #115 of 1016 ⚔️ AVTR vs RVTY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RVTY vs. AVTR, BIO, MTD, TXG)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Revvity Inc. (RVTY) ranks #115 by composite RQD confidence (65/100, grade C) and #74 by equity capitalization ($17.52B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while MTD leads on capital efficiency and profitability with 30.4% ROIC and 59.4% gross margin. MTD currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with RVTY at 65/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RVTY ACTIVE
Revvity Inc.
C 65/100 76.7x — 3.1% -5.30% $17.52B Benchmark Subject
AVTR
Avantor Inc.
D+ 56/100 — 32.7% -2.1% -3.78% $10.88B /avtr-vs-rvty →
BIO
Bio-Rad Laboratories Inc.
C 62/100 13.5x 51.9% 0.5% -3.18% $9.95B /bio-vs-rvty →
MTD
Mettler-Toledo International Inc.
B+ 78/100 39.6x 59.4% 30.4% -2.55% $33.56B /mtd-vs-rvty →
TXG
10x Genomics Inc.
C- 59/100 — 69.1% -5.7% -14.03% $9.13B /txg-vs-rvty →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-28 • CIK 0000031791

In its most recent audited fiscal period (FY2025, filed 2025-12-28), Revvity Inc. (RVTY) reported GAAP revenue of $2.86B (+3.7% vs. FY2024 revenue of $2.76B , and +3.8% cumulative change since FY2023) , GAAP net income of $241.2M, operating cash flow of $582.9M, and free cash flow of $509.4M (-6.0% YoY). On the balance sheet, RVTY closed FY2025 with $12.17B in total assets against $2.63B in total debt (Altman Z-Score: 3.37, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-28 $2.86B $241.2M $582.9M $509.4M $12.17B $2.63B
FY2024 (FY) 2024-12-29 $2.76B $270.4M $628.3M $541.7M $12.39B $3.15B
FY2023 (FY) 2023-12-31 $2.75B $693.1M $91.3M -$32.5M $10.17B $2.38B

3. RVTY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RVTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Revvity Inc. (NYSE: RVTY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $157.00 (-5.30% 1D, market cap $17.52B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, RVTY ranks #115 in composite RQD confidence.

How does RVTY compare to AVTR and BIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), RVTY carries a Roarable C (65/100 RQD), trailing P/E of 76.7x, gross margin of —, and ROIC of 3.1%. By comparison, AVTR (Avantor Inc.) holds a D+ grade (56/100 RQD, P/E N/A, ROIC -2.1%, cap $10.88B) and BIO (Bio-Rad Laboratories Inc.) posts a C grade (62/100 RQD, P/E 13.5x, ROIC 0.5%, cap $9.95B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while MTD leads on capital efficiency (30.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RVTY?

Per RVTY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-28, CIK 0000031791), Revvity Inc. generated $2.86B in revenue (+3.7% YoY), $241.2M in net income, and $509.4M in free cash flow against $12.17B in total assets and $2.63B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RVTY trading relative to its 50-day, 200-day, and 52-week technical levels?

RVTY last traded at $157.00 (-5.30% on volume of 3,180,178 shares), positioning the stock +6.95% above its 50-day simple moving average ($146.80) and +39.39% above its 200-day simple moving average ($112.63). Across its 52-week range of $81.22 to $169.06, RVTY sits at the 86.3% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($145.70 to $168.30).

RVTY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell RVTY stock right now?

Revvity Inc. (RVTY) currently earns a Roarable Rating of C (Hold — HOLD) with 65/100 RQD Confidence. Solid steady margins (3% return on capital), mixed timing at 77x P/E—hold if owned, no rush to chase.

What is RVTY's 12-month price target and RQD AI Jury consensus?

RVTY's 12-month base price target is $161.95 (range $126.32 to $191.1), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: RVTY RQD Cockpit RVTY 12M Forecast RVTY Earnings & Move RVTY Dividends & DRIP RVTY Insiders & 13F RVTY Whale Options RVTY Profit Sankey RVTY News & Why
ROARABLE RATING BRIEF • RQD 65/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RVTY — Revvity Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:13:55Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, RVTY scores 68 out of 100 (letter grade C+; verdict: Roarable Hold — Upper Neutral / Watch for Breakout). The five pillars are:

  • Fundamental Cash Engine (12/20): Per the Roarable RQD rating, ROIC is 3.1% and FCF yield is 2.75%. Both figures are modest, which limits the cash-generation argument for a prospective investor even though the score is not the lowest in the set.
  • Whale 13F Flow (19/20): The strongest pillar. Per the Roarable RQD rating, it reflects institutional accumulation and options positioning. For a prospective investor this signals that large holders have been building positions, though the specific holder data is not itemized in the source data.
  • Insider Conviction (9/20): The weakest pillar. Per the Roarable RQD rating, it reflects SEC Form 4 and Congressional PTR cluster flow. A low score here means insider and congressional activity provides less confirmation than institutional flow.
  • Macro Regime Fit (12/20): Per the Roarable RQD rating, beta is 0.95 and sector sensitivity is factored in. A beta near 1.0 implies market-like volatility, so the stock is not positioned as a defensive or high-beta play.
  • Forensic Balance Sheet (16/20): Per the Roarable RQD rating, Altman Z is 3.37, Piotroski F is 7/9, and Debt/Equity is 0.36. These are the most supportive forensic readings in the rating and suggest balance-sheet solvency is not a primary concern.

Investor implications: the upside case rests on institutional accumulation and balance-sheet strength. The valuation tradeoff is significant: per the market data, P/E (TTM) is 76.7 and EV/EBITDA is 48.2, which leaves limited room for error if cash-flow metrics do not improve. The "Watch for Breakout" label implies the rating treats the stock as near a decision point rather than a clear buy or sell. This is an educational read of the scores, not personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$165.78$18.5B76.771.348.22.160.18%0.95$81.22 - $169.063.1%

Business

Revvity Inc. (RVTY) is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Laboratory Analytical Instruments industry. Per the profile, the company operates with a market capitalization of $18.5B. The source data does not describe its specific products, customer base, or revenue model beyond sector and industry classification. Not available in source data for further business detail.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$2856.1M$356.6M$241.2MN/A$509.4M$919.9M$2631.2M
FY 2024$2755.0M$346.7M$270.4MN/A$541.7M$1163.4M$3150.5M
FY 2023$2750.6M$300.6M$693.1MN/A$-32.5MN/A$2380.8M

Per the SEC financials, revenue rose from $2750.6M (FY 2023) to $2856.1M (FY 2025), while net income declined from $693.1M to $241.2M over the same span. Per the market data, operating margin is 12.5% and net margin is 8.4%; gross margin is listed as 0%, which the source data does not explain. Per the market data, ROIC is 3.1%. Per the Roarable RQD rating, the Altman Z-Score is 3.37 and the Piotroski F-Score is 7/9. Per the SEC financials, debt declined from $3150.5M (FY 2024) to $2631.2M (FY 2025), and cash declined from $1163.4M to $919.9M over the same period.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, six headlines appear, each tagged YELLOW under the MARKET WIRE label:

  • A Yahoo Finance report frames RVTY as potentially "12% stretched on cash flow."
  • A Stocktwits profile page covers market action and institutional positioning.
  • A Trefis report notes a seven-day winning streak with the stock up 9.6%.
  • A Yahoo Finance report asks what is drawing fresh attention.
  • A Seeking Alpha report argues a high PEG ratio leaves limited near-term upside.
  • A Benzinga report covers Tuesday's stock movement.

Risk watch items: the recurring valuation and cash-flow concerns in the headlines align with the RQD scores and market multiples. Per the Butterfly Supply-Chain Graph, no proprietary signals are present; the graph lists supply chain as NONE and contains no links or signals.

Open Questions

  • What drives the gap between reported FY 2023 net income ($693.1M) and the FY 2025 figure ($241.2M), and is it recurring?
  • Why is gross margin listed as 0%, and does this reflect a data gap or a true reporting condition?
  • What specific institutional holders and options positions underlie the 19/20 whale flow score?
  • How do the declining cash and debt balances across FY 2024 to FY 2025 affect the forensic balance sheet read?
  • What analyst consensus and price targets exist, given that analyst data is unavailable?

RVTY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Revvity Inc. (RVTY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RVTY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RVTY Bull vs. Bear Conversation Board — What's Your Call at $157.00?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RVTY 🐻 50% BEARISH CONVICTION
1. Pick Your Side on RVTY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $179.04 (+8.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RVTY (C+ • RQD 68/100) a Buy at $165.78?

Welcome to the RVTY (Revvity Inc.) Roar Pit. Current RQD Composite is 68/100 (Roarable Hold — Upper Neutral / Watch for Breakout) in Biotechnology: Laboratory Analytical Instruments. Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (76.7x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $137.60 (-17.0%)
Spot @ $165.78

Pump the brakes on RVTY — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RVTY, but look at what you are paying: 76.7x trailing P/E with tightening sector spreads. Unless Revvity Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $190.65 (+15.0%)
Spot @ $165.78

RVTY cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RVTY, the market is fixating on short-term headline noise in Biotechnology: Laboratory Analytical Instruments and ignoring the balance sheet and cash flow trajectory. At $165.78 (52-wk range $81.22 - $169.06), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%